Market View

The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq broke below their respective 21-
DMA this week in heavy volume. The next level of support is the rising 50-DMA (S&P 500: 3,716; Nasdaq:

12,721), which the S&P 500 is currently testing. The distribution day count now stands at six and three, respec-
tively, with no further expiration next week.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq moved back into all-time highs this

week and are again trading near the upper end of their respective channels. Near-term support remains the ris-
ing 21-DMA (S&P 500: 3,776; Nasdaq: 13,045). The distribution day count stands at five and three, respec-
tively, with one day set to expire on each next week.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq pulled back off all-time highs this
week, consolidating sharp gains over the last several weeks. Both indices held above their respective 21-DMA
(S&P 500: 3,747; Nasdaq: 12,860), however, the S&P 500 picked up back-to-back distribution days to close the
week. The distribution day count now stands at five and three, respectively, with one day expiring on the S&P
500 next week.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq made new all-time highs for a sec-
ond straight week, continuing to hold trend above their respective 21-DMA (S&P 500: 3,718; Nasdaq: 12,732).

The distribution day count stands at four each, with one day expiring on each index next week.

Hansoh Pharma

Key points from this report:

 

  • Buy Hansoh Pharmaceutical. The stock is building the right side of a 29-week consolidation in good volume with a pivot of HKD 40.90.
  • New drugs included in reimbursement list. On December 28, Hansoh’s three newly launched drugs were included in China’s National Drug Reimbursement List.
  • Rich pipeline. During H1, Hansoh obtained clinical approvals of 10 drugs and filed marketing applications for an additional 10 drugs.
  • Leadership position in China’s psychotropic market. Hansoh is China’s largest psychotropic pharmaceutical company in terms of revenue, with a market share of ~9%.
  • Next catalyst: The company is expected to announce 2020 results in March. Consensus expects 16% y/y revenue growth and 9% y/y EPS growth in 2020. Consensus expects 25%+ revenue and earnings growth in 2021.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq closed the year at all-time highs
and above all major moving averages with limited distribution. Near-term support remains the rising 10- and
21-DMA (S&P 500: 3,689; Nasdaq: 12,612). The distribution day count stands at four and two, respectively,
with one day expiring on the S&P 500 next week.